abs209.txt	mek	inhibition	is	of	interest	in	cancer	drug	development		but	clinical	activityin	metastatic	colorectal	(mcrc)	has	been	limited	preclinical	studiesdemonstrated	wnt	pathway	overexpression	kras-mutant	cell	lines	resistant	tothe	inhibitor	selumetinib	the	combination	and	cyclosporin	a	noncanonical	modulator	demonstrated	antitumor	activity	mcrcpatient-derived	xenografts	to	translate	these	results	we	conducted	nci	cancertherapy	evaluation	program-approved	multicenter	phase	i/ib	trial	(nct02188264)	ofthe	patients	with	advanced	solidmalignancies	were	treated	oral	andcyclosporin	dose	escalation	followed	by	an	expansion	cohort	ofirinotecan	oxaliplatin-refractory	mcrc	utilized	asingle-agent	run-in	evaluate	fzd2	biomarker	upregulation	andkras-wt	kras-mt	stratification	identify	any	potential	predictors	ofefficacy	twenty	19	enrolled	expansionphases	respectively	most	common	adverse	events	grade	3/4	toxicitieswere	rash	hypertension	edema	three	dose-limiting	toxicities	(grade	3hypertension	increased	creatinine)	reported	mtd	wasselumetinib	75	mg	twice	daily	2	mg/kg	on	28-daycycle	kras	did	not	differences	response	betweenkras-wt	cancers	two	partial	responses	18	stable	disease	10progressive	observed	well	tolerated	evidence	futurestrategies	for	concept	include	identifying	better	improved	modulation	significance	findingstranslate	studies	combining	into	phasei	first-in-human	such	advancedsolid	malignancies	res	78(18)	5398-407	Â©2018	aacr
